The Alliance for Artificial Intelligence in Healthcare (AAIH)’s Post

BenevolentAI (OTC:BAIVF) has announced that chief technology officer James Malone will give a presentation at BioTechX Europe in Basel on Thursday, October 10 at 11:45am (CET). The presentation, titled ‘Building Trust and Explainability in Using AI in Drug Discovery’, will highlight the company's innovative R2E (Retrieve to Explain) system. R2E combines AI-driven information retrieval and explainable predictions to improve drug target identification. It processes complex queries and integrates biomedical data to enhance transparency in drug discovery. Malone will share data comparing R2E's performance with traditional methods, focusing on its success in predicting clinical trial outcomes. More at #Proactive #ProactiveInvestors http://ow.ly/5Wbp105Lwsg

Another proximity induced pharmacology collaboration- Matching modalities (and technologies) to targets/mechanisms! Looking forward to seeing fruits of this from the frontlines.

⭐ Monday's Speaker Spotlight ⭐ Yang-Ming Zhu, SVP, Head of Engineering at Superluminal Medicines Inc., will be sharing cutting-edge work using AI to unlock new therapeutic possibilities for G protein-coupled receptors (GPCRs) at this year's AI Driven Drug Discovery Summit (November 12-14, Boston). Session Focus: 🔍 ADME/Tox predictive models: Leveraging these models early and often to assess compound risks and liabilities. 🔍 Predictive docking: How this approach is transforming virtual screening by boosting throughput. 🔍 Generative AI: Integration in screening, hit expansion, and lead optimization. 📢 Latest News: Superluminal Medicines Inc. recently secured a $120M Series A led by Eli Lilly, aiming to advance six GPCR-focused drug programs. Their platform combines machine learning, chemistry, and generative biology to quickly develop new therapies, pushing boundaries in drug discovery. Join us to connect with leading innovators and thought leaders in AI-driven drug discovery this November! Book before THIS Friday for your LAST CHANCE to save: https://lnkd.in/eMxB9_EB #AIDDD #aidrivendrugdiscovery #aidrugdiscovery

#AI-enabled technologies are transforming different parts of the #biopharma industry value chain and creating new business opportunities. Explore Deloitte's collection of content surrounding biopharma industry trends with a focus on AI in biopharma.

Geometric deep learning in action! Congratulations to the VantAI team! #geometricdeeplearning

Biotech and big tech working together to improve on drug development’s current, meager 1-in-10 success rate. Here’s what AI can do: describe the contours of proteins that play a role in disease, comb vast chemical libraries for promising compounds, and improve the design and pace of clinical trials.

AI and Radiomics in Drug Development: Challenges and Approaches, Upcoming Webinar Hosted by Xtalks — PRBuzz.co — #pin this #free #webinar #gain insights into the pivotal #role of radiomics and #AI in #drug #development as well as their #potential in streamlining processes and enabling #precision #medicine The #featured #speakers will #share real-world applications and their #impact on the drug development landscape. TORONTO, #Jan #4 #2024 #Discover an informative webinar delving into the #important and potential impacts of radiomics and #artificial #intelligence

AI is everywhere. But it’s more than a buzz word. It’s humanity’s next Great Leap Forward. Towards precise, personalized, preventative medicine. Diseases that are fatal today, will be curable tomorrow. Recently, I shared some of my thoughts on how AI tools are already shaping the now and future of pharmacy and medicine: ✅ drug repurposing ✅ drug development ✅ drug response phenotypes To name the few. 🧏♀️ I would love to hear from you! How are you staying current with AI advancements? What are some other areas you think AI tools can help: lift administrative burden, help you do your job more efficiently, etc? 🤫 p.s. I have something exciting I have been working on to help me and you stay current in this rapidly changing world (😉coming this week) #pharmacogenomics #pharmacists #aiinhealthcare

Accelerating Drug Discovery: IDM Insight's AI powered Solution to Research Roadblocks Powered by AI: IDM Insight Seamlessly integrates advanced algorithms and machine learning to accelerate drug discovery. Prioritize compounds and targets based on therapeutic potential and utilize our Generative AI tool for novel molecule design. Access over 2 million compounds, from preclinical to approved drugs, in one comprehensive platform. Our databases stand out with unmatched comprehensiveness, integrating data from diverse sources for confident decision-making. Dive into physico-chemical properties, bioactivities, and more, aiding rational drug design. Explore interconnected databases for a holistic view of biological pathways and disease mechanisms, supporting drug readdressing and repurposing campaigns. Read the full article to discover how IDM Insight is shaping the future of medicinal chemistry. #DrugDiscovery #MedicinalChemistry #AIIntegration #ResearchInnovation #IDMInsight #ScienceAdvancements

At Poolbeg Pharma plc, we utilise creativity and advanced data to see opportunities and solutions where others may not. One example is that in AI-led drug development programmes, unlike other therapies which target the virus, we target the host response to stop or slow disease progression. Being patient-focused and leveraging AI technology allows us to find novel solutions that may be overlooked by others. For more information, click here: https://lnkd.in/dD-3rNup #POLB #AI #ArtificialIntelligence #POLBF #DrugDevelopment